Boston Scientific (NYSE:BSX) outlined strong 2025 results and issued guidance for continued growth in 2026, highlighting ...

The medical-device maker beats quarterly earnings expectations but offers a disappointing outlook for the current quarter.

Today, Feb. 4, 2026, investors are weighing Boston Scientific’s guidance against new deals and its long-term margin path.

Boston Scientific’s share price — which medical device competitors have long envied — sputtered Feb. 4 after the company ...

By Kamal Choudhury Feb 4 (Reuters) - Boston Scientific on Wednesday reported lower-than-expected quarterly sales in its key ...

Sales rose 16%, but the medical-device maker issued a soft forecast for the year, sending shares down premarket.

Boston Scientific (BSX) stock drops deespite Q4 2025 earnings beat as the company's Q1 2026 and full-year outlook fails to ...

Boston Scientific stock fell 8.4% despite beating Q4 earnings as weak Q1 guidance and electrophysiology division miss ...

Boston Scientific (NYSE: BSX) shares tumbled before hours today despite fourth-quarter results that topped the consensus ...

Pulsed field ablation has fueled strong sales growth for the firm’s electrophysiology business over the past two years.

Boston Scientific Corporation (NYSE: BSX) reported Q4 2025 revenues of $5.29B, beating management guidance and consensus estimate.

The company reported adjusted earnings of 80 cents per share, beating the consensus estimate of 78 cents, while revenue of $5.29 billion edged past forecasts of $5.28 billion. For the first quarter of ...